Houston, Texas-based OncoResponse, an immunotherapy company, has closed $40 million in Series B financing. RiverVest Venture Partners led the round.
Source: Press Release
Houston, Texas-based OncoResponse, an immunotherapy company, has closed $40 million in Series B financing. RiverVest Venture Partners led the round.
Source: Press Release
Copyright PEI Media
Not for publication, email or dissemination